* An article in the Aug. 16, 1995 issue of BioWorldToday should have paraphrased ZymoGenetics Inc.'spresident, Bruce Carter, as saying that his company'sagreement licensing thrombopoietin to Amgen Inc., ofThousand Oaks, Calif., does not affect Seattle-basedZymoGenetics potential $50 million collaboration withProgenitor Inc., of Columbus, Ohio.

* The quarterly earning report in the Aug. 15, 1995, issueof BioWorld Today incorrectly stated certain numbers forCentocor Inc. The company had $159.8 million in cashand equivalents on June 30, 1995 and 58.3 million sharesoutstanding.

(c) 1997 American Health Consultants. All rights reserved.